Showing results (21-30 of 120) with videos related to
Sort By:
Pageof 12
Internal Medicine (Tokyo, Japan)|January 5, 2017
Clinical Implication of Plasma Hydrogen Sulfide Levels in Japanese Patients with Type 2 DiabetesKunihiro Suzuki, Masaaki Sagara, Chie Aoki, et al.The Journal of Clinical Endocrinology and Metabolism|April 19, 2007
Retinol binding protein-4 levels and clinical features of type 2 diabetes patientsKohzo Takebayashi, Mariko Suetsugu, Sadao Wakabayashi, et al.Life Sciences|August 2, 2002
High glucose concentrations abolish the superoxide dismutase response of leukocytes to ascorbic acid or troglitazone in type 2 diabetes mellitusToshihiko Inukai, Keishi Takanashi, Kazumi Tayama, et al.Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|August 28, 2014
A Randomized Trial of Step-up Treatment with Premixed Insulin Lispro-50/50 vs. Aspart-70/30 in Patients with Type 2 Diabetes MellitusNozomi Domeki, Mihoko Matsumura, Tsuyoshi Monden, et al.Advances in Therapy|October 31, 2013
Improvement of glycemic control by re-education in insulin injection technique in patients with diabetes mellitusYuki Nakatani, Mihoko Matsumura, Tsuyoshi Monden, et al.Diabetes Care|August 28, 2003
Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intimal-media wall thickness in patients with type 2 diabetesYoshimasa Aso, Ki-Ichi Okumura, Kohzo Takebayashi, et al.Journal of Diabetes and Its Complications|September 5, 2020
Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysisShintaro Sakurai, Teruo Jojima, Toshie Iijima, et al.Southern Medical Journal|February 10, 2006
Correlation of high-sensitivity C-reactive protein and plasma fibrinogen with individual complications in patients with type 2 diabetesKohzo Takebayashi, Mariko Suetsugu, Rika Matsutomo, et al.Metabolism: Clinical and Experimental|March 26, 2002
Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1Yoshimasa Aso, Sachiko Matsumoto, Yukio Fujiwara, et al.Diabetes Care|August 27, 2005
Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitorYoshimasa Aso, Sadao Wakabayashi, Ruriko Yamamoto, et al.Pageof 12